托特罗定治疗Ⅲ型前列腺炎疗效观察

Efficacy and safety of tolterodine for treatment of men with chronic prostatitis(type Ⅲ)

目的观察并评价托特罗定治疗Ⅲ型前列腺炎疗效和安全性。方法将80例Ⅲ型慢性前列腺炎的门诊患者随机分为两组，每组各40例，两组均使用左氧氟沙星治疗，其中A组加用托特罗定和中成药（前列舒通）治疗，B组仅加用中成药（前列舒通）治疗。治疗6—8周后，通过NIH—CPSI评分评价两组治疗方法对患者的疗效。结果治疗后A组有效34例，有效率85％，B组有效24例，有效率60％，A组有效率高于B组（P〈0 .05）。结论对于Ⅲ型前列腺炎患者，托特罗定可明显改善患者排尿症状，且不良反应较低，患者耐受性较好。

Objective To evaluate the efficacy and safety of tolterodine for the treatment of men with chronic prostatitis （type Ⅲ）. Methods Eighty nlen with chronic prostatitis（type Ⅲ）were randomly assigned to receive a Chinese medicine（ n 40） or both tolterodine and a Chinese medicine（n 40） for 6 to 8 weeks. All the patients received oral levofloxacin simultaneously. Patient perception of treatment benefit,adverse reaction and NIH-CPSI were assessed. Results Patients receiving both toherodine and a Chinese medicine demonstrated sig- nificant improvement on NIH-CPSI than those receiving ouly a Chinese medicine. Conclusion Toherodine can improve the urinary, symptom effectively for men with prostatitis.